Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05063513 Withdrawn - Clinical trials for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

Autologous Stem Cell Transplantation: International Lupus Trial

ASTIL
Start date: July 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate remission induction therapy for refractory Lupus Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus Rituximab (anti CD20) followed by maintenance therapy with mycophenolate mofetil (MMF).

NCT ID: NCT04707924 Withdrawn - Clinical trials for Lupus Erythematosus, Cutaneous

Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Cutaneous Lupus erythematosus (CLE) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 - 73.2/100,000, predominantly in women in mid adulthood. Cutaneous lesions occur in about 75-80% of patients with systemic lupus erythematodes.These lesions unfortunately and invariably lead to significant scarring and postinflammatory hypo- and hyperpigmentation. Several studies have reported that laser treatments in patients with CLE have a positive effect and safety. However, only few case reports exist about the effect of ablative lasers such as Carbon Dioxide (CO2) and Erbium-doped Yttrium Aluminum Garnet (Er:YAG) lasers in CLE scarring. Although no study shows a flare-up of CLE after laser treatment of the scars, many physicians are afraid of treating these often stigmatizing scars. Considering the huge psychological impact of facial scaring on quality of life, it is essential to explore and assess the value of already well-established treatment options for the management of scars also in patients with cutaneous lupus erythematodes. Hereby the study seeks the subjective and objective improvement of the CLE-scars after treatment with fractional Er:YAG laser compared to control (untreated) areas.

NCT ID: NCT04060888 Withdrawn - Clinical trials for Lupus Erythematosus, Systemic

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Start date: July 14, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ustekinumab in Chinese participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard-of-care treatments.

NCT ID: NCT03937271 Withdrawn - Clinical trials for Rheumatoid Arthritis

Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome

Start date: April 1, 2019
Phase:
Study type: Observational

To explore the association among TCM pattern, TCM tongue diagnosis and TCM pulse diagnosis for Autoimmune disease and Dry eye syndrome

NCT ID: NCT03866317 Withdrawn - Clinical trials for Discoid Lupus Erythematosus

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch, skin pain, open sores, scarring, disfigurement and hair loss. Studies have shown that IL-17A may play a major role in inflammation and in the pathogenesis of discoid lupus. Treatment of discoid lupus sometimes is a challenge and unresponsive to current therapies. Secukinumab, an anti-IL-17A monoclonal antibody has been safe and effective in the treatment of psoriasis. The investigators propose to study the efficacy and safety of secukinumab in discoid lupus.

NCT ID: NCT03771885 Withdrawn - Clinical trials for Lupus Erythematosus, Systemic

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Start date: March 16, 2019
Phase: Phase 1
Study type: Interventional

The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus

NCT ID: NCT03204448 Withdrawn - Clinical trials for Systemic Lupus Erythematosus

Clinical Performance of BioCLIA Ro60

Start date: May 8, 2017
Phase:
Study type: Observational

The study is to evaluate the clinical performance of BioCLIA Ro60 for measuring the autoantibody in autoimmune disease patients.

NCT ID: NCT02920424 Withdrawn - Clinical trials for Lupus Erythematosus, Systemic

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Start date: June 30, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of JNJ-56022473 following multiple subcutaneous (SC) study agent administrations in subjects with Systemic Lupus Erythematosus (SLE) and to determine whether premedication with corticosteroids is required to improve the tolerability of SC JNJ-56022473.

NCT ID: NCT02779153 Withdrawn - Clinical trials for Systemic Lupus Erythematosus (SLE)

Acthar SLE (Systemic Lupus Erythematosus)

Acthar SLE
Start date: October 2016
Phase: Phase 4
Study type: Interventional

This is a randomized study exploring the efficacy, safety and steroid sparing ability of two doses (40 U and 80 U) of Acthar in SLE patients with immune mediated hematologic manifestations requiring steroid use for a minimum of 2 weeks prior to screening.

NCT ID: NCT02525835 Withdrawn - Clinical trials for Systemic Lupus Erythematosus

Tissue Sodium in Autoimmune Disease

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

This pilot study will test the hypothesis that a low sodium diet will decrease sodium (23Na) magnetic resonance imaging-determined skin sodium concentrations in patients with systemic lupus erythematosus (SLE) and improve blood pressure and inflammation